Last Updated on January 6, 2024 by The Health Master
The National Pharmaceutical Pricing Authority (NPPA) has fixed retail price of 8 formulations under Drugs Prices Control Order (DPCO) 2013 based on the decision of 83rd Authority Meeting dated January 27, 2021 vide its notification No. S.O. 523(E) dated 04-02-2021.
To read / download the notification No. S.O. 523(E) dated 04-02-2021, click here
The formulations include:
Rosuvastatin + aspirin capsule,
Escitalopram + clonazepam ,
Amlodipine & extended release metoprolol succinate tablet (Amlong MT 5/25),
Metoprolol tartrate 25mg (as extended release form),
Remogliflozin etabonate and metformin hydrochloride tablet ,
Remogliflozin etabonate and metformin hydrochloride tablet,
Paracetamol + mefenamic acid suspension.
Table
| Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
| 1. | Rosuvastatin + Aspirin Capsule | Each Capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg Aspirin IP 75mg (as enteric coated) | 1 Capsule | M/s Sun Pharma Laboratories Limited | 8.33 |
| 2. | Escitalopram + Clonazepam Tablet | Each film coated tablet contains: Escitalopram Oxalate IP eq. to Escitalopram 20mg, Clonazepam IP 0.5mg | 1 Tablet | M/s Sun Pharma Laboratories Limited | 18.19 |
| 3. | Amlodipine & Extended Release Metoprolol Succinate tablet (AMLONG MT 5/25) | Each film coated bilayered Tablet contains: Amlodipine Besilate IP eq. to Amlodipine 5mg Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg (As Extended Release form) | 1 Tablet | M/s Micro Labs Limited | 6.15 |
| 4. | Remogliflozin etabonate and Metformin hydrochloride tablet | Each film coated Tablet contains: Remogliflozin etabonate 100mg Metformin hydrochloride IP 1000mg | 1 Tablet | M/s Glenmark Pharmaceuticals Ltd. / M/s Intas Pharmaceuticals Ltd. | 13.18 |
| 5. | Remogliflozin etabonate and Metformin hydrochloride tablet | Each film coated Tablet contains: Remogliflozin etabonate 100mg Metformin hydrochloride IP 500mg | 1 Tablet | M/s Glenmark Pharmaceuticals Ltd. / M/s Intas Pharmaceuticals Ltd. | 11.44 |
| 6. | Azathioprine Tablet | Each film coated Tablet contains: Azathioprine IP 100mg | 1 Tablet | M/s RPG Life Sciences Limited | 8.69 |
| 7. | Paracetamol + Mefenamic Acid Suspension | Each 5ml contains: Paracetamol IP 125mg, Mefenamic Acid IP 50mg | 1 ML | M/s Aristo Pharmaceuticals Pvt. Ltd. | 0.58 |
| 8. | Paracetamol + Mefenamic Acid Suspension | Each 5ml contains: Paracetamol IP 250mg, Mefenamic Acid IP 100mg | 1 ML | M/s Aristo Pharmaceuticals Pvt. Ltd. | 0.66 |
The manufacturer of these formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified. The manufacturer may add goods and services tax only if they have paid actually or it is payable to the government on the retail price as prescribed by NPPA.
The retail price for a pack of these formulations shall be arrived at by the concerned manufacturer in accordance with the retail price specified as per provisions contained in paragraph 11 of the DPCO, 2013.
The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller (SDC) and dealers.
Also read:
Latest Notifications: D&C Rules 1945
Latest Notifications: D&C Act 1940
As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
The retail price fixed is applicable only to the individual manufacturer/marketer as specified i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO 2013.
In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
Follow and connect with us on Facebook and Linkedin
Go to main website, click here
Subscribe for daily free updates, click here
For daily free updates on WhatsApp, click here
